Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old

NCT04313127 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT04313127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2020
Completion date
February 20, 2021
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19